We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Laser-Based Imaging Technique Enables Much Faster Tissue Diagnosis during Tumor Surgery

By LabMedica International staff writers
Posted on 26 Oct 2023
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)
Image: A new AI technique enables rapid digital tissue analysis for brain tumor surgery (Photo courtesy of Medical University Vienna)

The central nervous system can have around 120 different kinds of tumors, and the first step in treating them generally involves surgery along with acquiring histological samples. During this procedure, a small part of the tumor is excised and a histological frozen section is readied in the neuropathology department to better understand the tumor's features. Now, a newly developed laser-based imaging method allows neuropathologists to generate a report in just a matter of minutes.

Surgeons at Medical University Vienna (Vienna, Austria) have started employing this novel laser-based imaging method that considerably speeds up tissue diagnosis during tumor surgeries. Using Stimulated Raman Histology (SRH), a digital cross-section of the tissue can be instantly created right in the surgical suite, enabling a diagnosis within just a few minutes. In comparison, the standard method involving tissue transportation, manual preparation, and analysis usually takes around 30 minutes on an international average.

One of the advantages of this technique is that since the tissue is examined in its natural, untreated form, it remains fully available for any subsequent, more in-depth diagnostic tests. If SRH detects diagnostic tumor tissue, needle biopsies can also be concluded much more quickly. These procedures are not applicable just to brain tumors but can also be utilized for confirming diagnoses of other neurological conditions like blood vessel inflammatory diseases and demyelinating lesions. Initially developed in the United States, the SRH method was first adopted in Europe at the Department of Neurosurgery of MedUni Vienna and University Hospital Vienna, led by Georg Widhalm. A research study at MedUni Vienna showed a 99% correlation between digital histology and conventional frozen section.

"The new technology enables surgeons to make faster decisions regarding the optimal surgical strategy in the operating room, which significantly reduces the time in the operating room for patients. In addition, the safety of the procedure is also increased," said Georg Widhalm.

Related Links:
Medical University Vienna 

Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
New
Gold Member
Serum Indices Control
Acusera Serum Indices Control
New
Gastrointestinal Panel
Xpert® GI Panel

Channels

Clinical Chemistry

view channel
Image: Tracking blood test trends alongside unexplained weight loss may help identify patients at increased cancer risk and support earlier investigation (Image Credit: 123RF)

Blood Test Patterns Improve Cancer Risk Assessment in Primary Care

Unexplained weight loss is a common but nonspecific presentation in primary care that can precede several types of cancer, making referral decisions difficult. Routine blood tests may produce borderline... Read more

Molecular Diagnostics

view channel
Image: NTM are about 200 environmental bacteria found in soil and water that can cause chronic, tuberculosis-like lung infections but are distinct from the Mycobacterium tuberculosis complex (Image Credit: Adobe Stock)

Rapid CRISPR Test Identifies Nontuberculous Mycobacteria Species from Respiratory Samples

Chronic lung infections caused by nontuberculous mycobacteria (NTM) are increasingly recognized but frequently mistaken for tuberculosis, complicating diagnosis and care. These infections may affect as... Read more

Immunology

view channel
Image: Although many people harbor latent Epstein-Barr virus (EBV), growing evidence has linked the virus to MS pathobiology (Image Credit: Adobe Stock)

Blood EBV Activity Biomarkers May Predict Multiple Sclerosis Relapse Months Ahead

Predicting relapse in multiple sclerosis (MS) remains difficult, limiting opportunities for timely intervention and monitoring. Although many people harbor latent Epstein-Barr virus (EBV), growing evidence... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Pathology

view channel
Image Credit: Adobe Stock

Machine Learning Cytology Tool Improves Cancer Cell Identification

Cytological screening remains central to early cancer detection, but its accuracy depends heavily on expert interpretation of stained cells. Under conventional microscopy, malignant and reactive cells... Read more

Technology

view channel
Image: ADLM recommends that emerging AI tools follow the same professional oversight, quality, validation, and monitoring standards as traditional clinical testing within CLIA’s existing framework (Image Credit: Adobe Stock)

ADLM Calls for CLIA Updates to Support Safe AI Use in Laboratory Medicine

Clinical laboratories increasingly use artificial intelligence to verify, interpret, and report results, but safeguards under the Clinical Laboratory Improvement Amendments (CLIA) were designed in 1992.... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more